Drug name: Liposomal Daunorubicin + Tamoxifen


Related CSCTT Targets

ABCG2 [ref.1]Q9UNQ0
ABCB1 [ref.1]P08183

Daunorubicin

Cas.no PubChem ID
20830-81-3 30323
Known Target
DNA
DNA topoisomerase 2-alphaP11388
DNA topoisomerase 2-betaQ02880
Structure
...
Introduction
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.

Tamoxifen

Cas.no PubChem ID
10540-29-1 2733526
Known Target
Estrogen receptorP03372
Estrogen receptor betaQ92731
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseQ15125
PKC family
Structure
...
Introduction
One of the selective estrogen receptor modulators (SERM) with tissue-specific activities for the treatment and prevention of estrogen receptor positive breast cancer. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the endometrium.

Reference

  • [1] Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells. Guo, J., et al. (2010).J Pharm Pharm Sci. 13(2):136-51.
    20816001. [ 20816001 ]

Back to top